Muddy Waters-St Jude: heart attack

An artificial pacemaker (serial number 1723182) from St. Jude Medical, with electrode.

Despite a series of good bets, the hedge fund’s short call on devices maker is challenged


Fund claims device maker open to hackers

Muddy Waters uses alleged cyber flaws to target St Jude Medical

Mylan pricked into EpiPen price cut

Clinton among critics to slam cost of anaphylactic shock treatment

©Epipen Media Room

Mylan: pen is not mightier

Drug group has yet to justify the pricing on Epipen

Spire Healthcare

Spire aims to gain from NHS funding gap

UK healthcare group to invest £190m in new and expanded hospitals

Brexit offers opportunities to UK science

Britain needs light touch regulation similar to Switzerland to be global leader, writes John Bell

Breast cancer test raises hope of avoiding chemo

Genetic check may help early-stage patients avoid toxic follow-up

Clinton and White House join Mylan furore

Democratic nominee urges cut in ‘outrageous’ price of EpiPen

Pfizer snaps up AstraZeneca antibiotics

Anglo-Swedish drugmaker says $1.6bn sale will allow it to concentrate on core areas

Caring doctor or nurse holding elderly ladys hands in wheelchair.

Four Seasons in talks with bondholders

Care home operator wants resolution by the end of year

The risk of marginal weight gains

Being even slightly overweight can increase chance of early death

Pfizer looks to conquer cancer with deal

$14bn move on Medivation is part of strategy to lead in oncology

Pfizer makes $14bn bet on cancer drugs

World’s second-biggest pharmaceuticals company aims to become leading player in oncology

Pfizer/Medivation: combination therapy

Pfizer must hope for performance that justifies the premium paid

Circle wins NHS services deal in London

Award of contract highlights trend towards outsourcing in Britain’s state-run health system

Pfizer nears $14bn takeover of Medivation

US drug company set to win auction for California biotech group

Pharmaceuticals: Staying power

FT analysis shows big pharma makes billions after patents lapse

US doctors waste millions on branded drugs

Big pharma groups make more than $1bn in six months as cheap generics overlooked by prescribers

Stada faces showdown with activist

AOC seeks to clear out German generic drugmaker’s board

Political Diary

Leaders of Germany, France and Italy discuss post-Brexit EU


More FT Twitter accounts